KDR and neoplasm: The anti-VEGFR and FGFR treatment, such as surufatinib, could suppress tumor angiogenesis and overcome the resistance to VEGF/VEGFR inhibition, thus enhance the effect of immune check point inhibitors (Zhou et al. 2017).